Lisuride in parkinsonism.
Lisuride is a soluble ergolene derivative with endocrine effects similar to but more potent than those of bromocriptine. In nine subjects with idiopathic, postencephalitic, or drug-induced parkinsonism, lisuride at a dosage of 0.05 to 0.15 mg intravenously caused an immediate improvement in tremor, rigidity, akinesia, and postural deformity, but also caused chorea and orofacial dyskinesia. Improvement lasted 2 to 3 hours. Lisuride had little or no effect in a single patient with progressively supranuclear palsy. Oral lisuride therapy, 0.8 to 4.8 mg daily, had similar effects but occasionally caused reduced awareness and hallucinations.
D000284:Administration, Oral; D000368:Aged; D001562:Benzimidazoles / Q000008:administration & dosage; D002819:Chorea / Q000139:chemically induced; D004294:Domperidone; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007275:Injections, Intravenous; D008090:Lisuride / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010243:Paralysis / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010880:Piperidines / Q000008:administration & dosage; D011388:Prolactin / Q000097:blood
D001562:Benzimidazoles; D004873:Ergolines; D010880:Piperidines; D004294:Domperidone; D011388:Prolactin; D013006:Growth Hormone; D008090:Lisuride